Netherlands-based global health technology company myTomorrows announced on Wednesday that it has named Iskra Reic, as its new independent director, effective immediately.
Reic, a seasoned healthcare executive, has decades of pharmaceutical industry leadership, strong product development and global commercialisation expertise.
Previously Reic served at AstraZeneca in various global leadership roles, including leading the Europe, and Canada business, she also served on the senior executive Team. Currently, Reic manages AstraZeneca's global vaccines and immune therapies pipeline and portfolio, including research and development, medical affairs, and commercial operations. Reic had earlier joined the Steering Committee for the Partnership for Health System Sustainability and Resilience.
Michel van Harten, myTomorrows CEO, said, 'We are delighted to welcome Reic to the Board. Her world-class experience in the BioPharmaceutical industry, combined with her leadership in management and development, will be invaluable in furthering myTomorrows' goal of empowering patients through their treatment journeys with greater confidence and knowledge.'
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies